- P-ISSN 1010-0695
- E-ISSN 2288-3339
Objectives: Galgeun-tang (GGT, gegen-tang, kakkon-to), an herbal formula, is used to treat the common cold, fevers, headaches, hangovers and neck and upper back stiffness. The drugs currently used to treat atopic dermatitis (AD) are limited by the significant adverse effects associated with their long-term usage. The need to efficiently manage the AD response while reducing side effects has led to the development of alternative remedies. Methods: To assess the effects of GGT on AD, the anti-inflammatory and anti-AD properties of GGT were evaluated in both in vitro and in vivo systems. Results: Nitric oxide (NO) and histamine production on lipopolysaccharide (LPS)-treated RAW264.7 cells and phorbol-12 myristate 13-acetate (PMA)/A23187-treated MC/9 cells, respectively, were inhibited by GGT. GGT reduced thymus and activation-regulated chemokine (TARC/CCL17) release on TNF-α/IFN-γ stimulated HaCaT cells in a dose-dependent manner. GGT reduced both plasma levels of IgE and histamine and the dermatitis score in house dust mite induced atopic dermatitis-like lesions on NC/Nga mice. However, there were no significant histopathological differences observed between the GGT group and the AD-induced group, such as AD-like lesions in the dorsal skin or ear or mast cell infiltration in the dorsal skin. Conclusions: These results indicate that GGT inhibits chemokine production by keratinocytes and the atopic dermatitis response in NC/Nga mice, suggesting that GGT may be useful as a therapeutic remedy for treating AD and allergic inflammation-related diseases.
1. Terui T. Analysis of the mechanism for thedevelopment of allergic skin inflammation andthe application for its treatment: overview of thepathophysiology of atopic dermatitis. JPharmacol Sci 2009;110(3):232-6.
2. Nagai H, Teramachi H, Tuchiya T. Recentadvances in the development of anti-allergicdrugs. Allergol Int 2006;55(1):35-42.
3. Aoyama H, Tabata N, Tanaka M, Uesugi Y,Tagami H. Successful treatment of resistantfacial lesions of atopic dermatitis with 0.1%FK506 ointment. Br J Dermatol 1995;133(3):494-6.
4. Hanifin JM, Cooper KD, Ho VC, Kang S,Krafchik BR, Margolis DJ, et al. Guidelines ofcare for atopic dermatitis, developed inaccordance with the American Academy ofDermatology (AAD)/American Academy ofDermatology Association "AdministrativeRegulations for Evidence-Based Clinical PracticeGuidelines". J Am Acad Dermatol 2004;50(3):391-404.
5. Boguniewicz M, Fiedler VC, Raimer S,Lawrence ID, Leung DY, Hanifin JM. Arandomized, vehicle-controlled trial oftacrolimus ointment for treatment of atopicdermatitis in children. Pediatric TacrolimusStudy Group. J Allergy Clin Immunol1998;102(4 Pt 1):637-44.
6. Tomi NS, Luger TA. The treatment of atopicdermatitis with topical immunomodulators. ClinDermatol 2003;21(3):215-24.
7. Kurokawa M, Tsurita M, Brown J, Fukuda Y,Shiraki K. Effect of interleukin-12 levelaugmented by Kakkon-to, a herbal medicine, onthe early stage of influenza infection in mice.Antiviral Res 2002;56(2):183-8.
8. Wu MS, Yen HR, Chang CW, Peng TY, HsiehCF, Chen CJ, et al. Mechanism of action of thesuppression of influenza virus replication byKo-Ken Tang through inhibition of thephosphatidylinositol 3-kinase/Akt signalingpathway and viral RNP nuclear export. JEthnopharmacol 2011;134(3):614-23.
9. Yamamoto T, Fujiwara K, Yoshida M,Kageyama-Yahara N, Kuramoto H, Shibahara N,et al. Therapeutic effect of kakkonto in a mousemodel of food allergy with gastrointestinalsymptoms. Int Arch Allergy Immunol 2009;148(3):175-85.
10. Ishijima Y, Kawamura T, Kimura A, Kohno A,Okada T, Tsuji T, et al. Toll-like receptor4-dependent adjuvant activity of Kakkon-toextract exists in the high molecular weightpolysaccharide fraction. Int J ImmunopatholPharmacol 2011;24(1):43-54.
11. Firenzuoli F, Gori L. Herbal medicine today:clinical and research issues. Evid BasedComplement Alternat Med 2007;4(Suppl 1):37-40
12. Cheng CW, Bian ZX, Wu TX. Systematic reviewof Chinese herbal medicine for functionalconstipation. World J Gastroenterol. 2009;15(39):4886-95.
13. Seo CS, Kim JH, Shin HK. SimultaneousDetermination of Albiflorin, Cinnamaldehyde,Cinnamic Acid, Daidzin, Glycyrrhizin, Liquiritin,Paeoniflorin and Puerarin in Galgeun-tang byHPLC-PDA. J Korean Orient Med 2010;31(6):8-15.
14. Asl MN, Hosseinzadeh H. Review ofpharmacological effects of Glycyrrhiza sp. andits bioactive compounds. Phytother Res2008;22(6):709-24.
15. Jiang D, Chen Y, Hou X, Xu J, Mu X, ChenW. Influence of Paeonia lactiflora roots extracton cAMP-phosphodiesterase activity and relatedanti-inflammatory action. J Ethnopharmacol2011;137(1):914-20.
16. Tung YT, Chua MT, Wang SY, Chang ST.Anti-inflammation activities of essential oil andits constituents from indigenous cinnamon(Cinnamomum osmophloeum) twigs. BioresourTechnol 2008;99(9):3908-13.
17. Yang X, Hu W, Zhang Q, Wang Y, Sun L.Puerarin inhibits C-reactive protein expressionvia suppression of nuclear factor kappaBactivation in lipopolysaccharide-induced peripheralblood mononuclear cells of patients with stableangina pectoris. Basic Clin Pharmacol Toxicol2010;107(2):637-42.
18. Sumiyoshi K, Nakao A, Setoguchi Y, Tsuboi R,Okumura K, Ogawa H. TGF-beta/Smad signalinginhibits IFN-gamma and TNF-alpha-inducedTARC (CCL17) production in HaCaT cells. JDermatol Sci 2003;31(1):53-8.
19. Romagnani S. Cytokines and chemoattractants inallergic inflammation. Mol Immunol 2002;38(12-13):881-5.
20. Hirota T, Saeki H, Tomita K, Tanaka S, Ebe K,Sakashita M, et al. Variants of C-C motifchemokine 22 (CCL22) are associated withsusceptibility to atopic dermatitis: case-controlstudies. PLoS One 2011;6(11):e26987.
21. Shimada Y, Takehara K, Sato S. Both Th2 andTh1 chemokines (TARC/CCL17, MDC/CCL22,and Mig/CXCL9) are elevated in sera frompatients with atopic dermatitis. J Dermatol Sci2004;34(3):201-8.
22. Fukuyama T, Tajima Y, Hayashi K, Ueda H,Kosaka T. Prior or coinstantaneous oral exposureto environmental immunosuppressive agentsaggravates mite allergen-induced atopicdermatitis-like immunoreaction in NC/Nga mice.Toxicology 2011;289(2-3):132-40.
23. US Department of Health and Human Services,Food and Drug Administration, Center for DrugEvaluation and Research. Guidance for industryon estimating the maximum safe starting dose ininitial clinical trials for therapeutics in adulthealthy volunteers. 2005. Available at: URL:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf.